Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated therapeutics for the treatment of skin diseases. Our current pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, atopic dermatitis, contact dermatitis, acne and psoriasis.
Brickell's Phase 2b Study Results for BBI-4000 Presented at the Late-breaking Research Forum during the 74th American Academy of Dermatology Annual Meeting.
Brickell Announces Positive Phase 2b Results for BBI-4000 (Sofpironium Bromide) in Patients with Hyperhidrosis.
Brickell Secures Exclusive WW Rights to Novel Series of RORγ Inhibitors as Potential Topical Therapy for Psoriasis.